Skip to main content
رجوع
JCRRF logo

JCR Pharmaceuticals Co., Ltd.

جودة البيانات: 100%
ذروة بيع
JCRRF
OTC Healthcare Drug Manufacturers - General
KWD 4.17
KWD 0.00 (0.00%)
القيمة السوقية: 508.67M
نطاق اليوم
KWD 4.17 KWD 4.25
نطاق 52 أسبوعًا
KWD 3.78 KWD 5.00
حجم التداول
1,200
متوسط 50 يوم / 200 يوم
KWD 4.33 / KWD 4.45
الإغلاق السابق
KWD 4.17

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -0.1 0.3
P/B 0.0 2.9
ROE % -9.2 3.7
Net Margin % -14.4 3.8
Rev Growth 5Y % 2.4 10.0
D/E 0.8 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 29.307
KWD 26.306 – KWD 32.484
40 B 1
FY2029 KWD 16.123
KWD 14.472 – KWD 17.871
38 B 1
FY2028 KWD 14.491
KWD 13.007 – KWD 16.061
38 B 1

النقاط الرئيسية

Revenue grew 2.39% annually over 5 years — modest growth
Earnings declined -186.42% over the past year
Negative free cash flow of -15.37B
PEG of 0.10 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 25.25%

النمو

Revenue Growth (5Y)
2.39%
Revenue (1Y)-22.86%
Earnings (1Y)-186.42%
FCF Growth (3Y)N/A

الجودة

Return on Equity
-9.22%
ROIC-5.86%
Net Margin-14.39%
Op. Margin-20.11%

الأمان

Debt / Equity
0.81
Current Ratio1.16
Interest Coverage-42.90

التقييم

P/E Ratio
-0.11
P/B Ratio0.01
EV/EBITDAN/A
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -22.86% Revenue Growth (3Y) -1.87%
Earnings Growth (1Y) -186.42% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 2.39% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 33.07B Net Income (TTM) -4.76B
ROE -9.22% ROA -4.54%
Gross Margin 65.73% Operating Margin -20.11%
Net Margin -14.39% Free Cash Flow (TTM) -15.37B
ROIC -5.86% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.81 Current Ratio 1.16
Interest Coverage -42.90 Dividend Yield 0.03%
Valuation
P/E Ratio -0.11 P/B Ratio 0.01
P/S Ratio 0.02 PEG Ratio 0.10
EV/EBITDA N/A Dividend Yield 0.03%
Market Cap 508.67M Enterprise Value 25.42B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 33.07B 42.87B 34.34B 51.08B 30.09B
Net Income -4.76B 5.51B 3.77B 14.51B 6.89B
EPS (Diluted) -38.43 43.92 30.22 116.79 55.52
Gross Profit 21.74B 31.25B 25.46B 40.62B 22.27B
Operating Income -6.65B 7.53B 4.98B 19.93B 8.27B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 104.86B 102.23B 94.94B 97.13B 73.78B
Total Liabilities 57.42B 45.75B 42.53B 46.05B 35.23B
Shareholders' Equity 47.04B 56.18B 52.16B 50.88B 38.38B
Total Debt 38.11B 23.30B 22.80B 18.10B 18.10B
Cash & Equivalents 13.20B 18.76B 13.28B 30.73B 26.26B
Current Assets 51.06B 57.58B 47.80B 62.19B 48.55B
Current Liabilities 43.99B 30.14B 35.76B 42.05B 29.03B